PITTSTON, ME--(Marketwire - Mar 6, 2013) - YaFarm Technologies, Inc. (
The ISCI is a premier provider of cell-based, regenerative medical therapies that utilize a patient's own stem cells for the treatment of neuro-degenerative diseases. Combining a state-of-the-art laboratory and clean room facility with an integrative medical approach to treatment, the ISCI provides therapies as part of controlled clinical studies. The ISCI has partnered with the International Stem Cell Practice (ISCP) to provide patients with access to a global network of physicians to provide pre-treatment evaluation and post-therapy follow up for the independent collection and evaluation of patient outcomes.
The investment will be used to complete the construction of the new medical facility housed within Hospital Galenia in Cancun, Mexico. The hospital is accredited by both the Joint Commission (JCI) and the Accreditation Canada (ACI), and is the only hospital in Mexico to have been awarded certification from both of these organizations.
"The funding is important," says David Audley, CEO of the ISCI. "The pace of work for both the laboratory facility and the clean room space is moving fast, and this final infusion of capital will allow us to complete the project earlier than scheduled." Once finished, the ISCI will be able to initiate the clinical studies for diseases such as Parkinson's, Alzheimer's and Multiple Sclerosis.
"This last stage financing allows us to deliver these therapies to patients sooner than we expected," continues Mr Audley. "With a state-of-the-art lab, a world-class medical facility and a truly integrative treatment approach represent the next great stage of cell-based medicine, and patient care."
About Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.
- Investment & Company Information